Effectiveness of novel iron regulators in the treatment of diabetic nephropathy

Dekai Banerjee, Ginpreet Kaur, Bappaditya Chatterjee, Hemant Joshi, Seema Ramniwas, Hardeep Singh Tuli
{"title":"Effectiveness of novel iron regulators in the treatment of diabetic nephropathy","authors":"Dekai Banerjee, Ginpreet Kaur, Bappaditya Chatterjee, Hemant Joshi, Seema Ramniwas, Hardeep Singh Tuli","doi":"10.15584/ejcem.2023.3.28","DOIUrl":null,"url":null,"abstract":"Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.","PeriodicalId":11828,"journal":{"name":"European Journal of Clinical and Experimental Medicine","volume":"70 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical and Experimental Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15584/ejcem.2023.3.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型铁调节剂治疗糖尿病肾病的有效性
介绍和目的。即将到来的用于治疗糖尿病肾病的铁调节剂的新进展涉及联合螯合治疗的共同表现,用于消除与炎症和铁失衡相关的终末期肾脏疾病,这是由肾铁吸收改变的。然而,铁在过滤血液的聚集性肾脏中的积累可能会导致影响糖尿病血糖调节的问题。材料和方法。采用精心设计的方法,发现铁螯合剂及其治疗糖尿病肾病的潜力的相关研究出版物。在Google Scholar、Web of Science、PubMed和EMBASE中搜索“铁螯合剂”、“糖尿病肾病”、“终末期肾病”和“螯合疗法”。文学分析。虽然具体的病因和发展尚未完全探索,但铁病理生理学的新证据有助于理解急性肾损伤和慢性肾脏疾病的发病机制,这至关重要地提供了新的铁螯合治疗技术。铁下垂和hepcidin标记蛋白增加氧化/硝化应激和肾损伤。铁螯合剂药物包括去铁胺、去铁铁素和去铁酮作为预防策略进行了测试。结论。本文涵盖了铁螯合剂的临床前和临床方面,以避免糖尿病肾病,包括在选择剂量方案时必须审查的新型铁疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
期刊最新文献
Traditional teaching method versus simulation-based teaching method in the prevention of medication errors among nursing students Simplified vs modified (reduced) ultrasound 6 joint score in assessing disease activity in rheumatoid arthritis patients Comparison of algorithms for detection of active inflammatory lesions in sacroiliitis Effect of clinic-based and telemonitored home-based intervention on pain intensity, functioning and quality of life in patients with knee osteoarthritis Assessment of preoperative anxiety and negative automatic thoughts in patients waiting for corneal transplantation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1